Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Budgets | 1 | 2012 | 10 | 0.420 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2012 | 28 | 0.420 |
Why?
|
Research Support as Topic | 1 | 2012 | 26 | 0.420 |
Why?
|
Biomedical Research | 1 | 2012 | 155 | 0.370 |
Why?
|
Cachexia | 1 | 2010 | 7 | 0.350 |
Why?
|
Lipolysis | 1 | 2010 | 17 | 0.350 |
Why?
|
Biological Factors | 1 | 2010 | 11 | 0.350 |
Why?
|
Adipose Tissue | 1 | 2010 | 347 | 0.280 |
Why?
|
DNA | 5 | 2012 | 228 | 0.280 |
Why?
|
Membrane Glycoproteins | 1 | 2006 | 102 | 0.270 |
Why?
|
Pepsin A | 4 | 2007 | 8 | 0.270 |
Why?
|
Gastroesophageal Reflux | 4 | 2007 | 26 | 0.260 |
Why?
|
Ovarian Neoplasms | 1 | 2006 | 94 | 0.260 |
Why?
|
Light | 4 | 2011 | 24 | 0.210 |
Why?
|
DNA, Catalytic | 3 | 2010 | 4 | 0.180 |
Why?
|
Molecular Sequence Data | 6 | 2012 | 356 | 0.170 |
Why?
|
Gene Expression Regulation | 2 | 2011 | 494 | 0.150 |
Why?
|
Amino Acid Sequence | 5 | 2012 | 283 | 0.150 |
Why?
|
Escherichia coli | 2 | 2007 | 87 | 0.140 |
Why?
|
Serine Endopeptidases | 2 | 2006 | 20 | 0.130 |
Why?
|
Nucleic Acid Conformation | 2 | 2012 | 48 | 0.120 |
Why?
|
Transcription, Genetic | 2 | 2012 | 137 | 0.120 |
Why?
|
Ultraviolet Rays | 3 | 2009 | 51 | 0.120 |
Why?
|
Membrane Proteins | 2 | 2006 | 257 | 0.120 |
Why?
|
Recombinant Proteins | 3 | 2012 | 247 | 0.110 |
Why?
|
Culture Media, Conditioned | 2 | 2012 | 51 | 0.110 |
Why?
|
Ubiquinone | 1 | 2013 | 7 | 0.110 |
Why?
|
DNA Restriction Enzymes | 2 | 2009 | 5 | 0.110 |
Why?
|
Benzodioxoles | 2 | 2009 | 6 | 0.110 |
Why?
|
Fatigue | 1 | 2013 | 85 | 0.110 |
Why?
|
Academies and Institutes | 1 | 2012 | 5 | 0.110 |
Why?
|
Salaries and Fringe Benefits | 1 | 2012 | 10 | 0.110 |
Why?
|
Financing, Government | 1 | 2012 | 10 | 0.110 |
Why?
|
Faculty | 1 | 2012 | 17 | 0.100 |
Why?
|
Vitamins | 1 | 2013 | 68 | 0.100 |
Why?
|
Research Personnel | 1 | 2012 | 15 | 0.100 |
Why?
|
Matrix Metalloproteinases | 1 | 2012 | 11 | 0.100 |
Why?
|
Ephrin-A1 | 1 | 2012 | 11 | 0.100 |
Why?
|
Models, Molecular | 3 | 2007 | 193 | 0.100 |
Why?
|
Oligonucleotides | 1 | 2012 | 30 | 0.100 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2012 | 80 | 0.100 |
Why?
|
Photic Stimulation | 1 | 2012 | 158 | 0.100 |
Why?
|
Mutagenesis, Site-Directed | 2 | 2009 | 62 | 0.100 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2011 | 17 | 0.100 |
Why?
|
Bacterial Proteins | 2 | 2009 | 90 | 0.100 |
Why?
|
Peroxidase | 2 | 2008 | 31 | 0.100 |
Why?
|
Mice | 4 | 2010 | 2475 | 0.100 |
Why?
|
NF-kappa B | 1 | 2011 | 81 | 0.090 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2012 | 261 | 0.090 |
Why?
|
Polymerase Chain Reaction | 2 | 2009 | 197 | 0.090 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 1 | 2010 | 5 | 0.090 |
Why?
|
Substrate Specificity | 5 | 2009 | 87 | 0.090 |
Why?
|
Seminal Plasma Proteins | 1 | 2010 | 3 | 0.090 |
Why?
|
3T3-L1 Cells | 1 | 2010 | 11 | 0.090 |
Why?
|
Palmitic Acid | 1 | 2010 | 12 | 0.090 |
Why?
|
Serum | 1 | 2010 | 19 | 0.090 |
Why?
|
Cell Size | 1 | 2010 | 38 | 0.090 |
Why?
|
Animals | 7 | 2010 | 7466 | 0.090 |
Why?
|
Tumor Burden | 1 | 2010 | 60 | 0.090 |
Why?
|
Neoplasm Transplantation | 1 | 2010 | 73 | 0.090 |
Why?
|
Time Factors | 3 | 2010 | 2152 | 0.090 |
Why?
|
Tumor Cells, Cultured | 1 | 2010 | 168 | 0.090 |
Why?
|
Rats, Inbred F344 | 1 | 2010 | 133 | 0.090 |
Why?
|
Thymidine | 1 | 2009 | 6 | 0.090 |
Why?
|
Alkenes | 1 | 2009 | 1 | 0.090 |
Why?
|
Nitro Compounds | 1 | 2009 | 4 | 0.090 |
Why?
|
Glutathione Transferase | 1 | 2009 | 13 | 0.080 |
Why?
|
Random Allocation | 1 | 2010 | 220 | 0.080 |
Why?
|
DNA-Directed DNA Polymerase | 1 | 2009 | 15 | 0.080 |
Why?
|
Mutagenesis | 1 | 2009 | 33 | 0.080 |
Why?
|
PPAR gamma | 1 | 2009 | 46 | 0.080 |
Why?
|
Sarcoma | 1 | 2010 | 71 | 0.080 |
Why?
|
Plague Vaccine | 1 | 2008 | 1 | 0.080 |
Why?
|
Pore Forming Cytotoxic Proteins | 1 | 2008 | 4 | 0.080 |
Why?
|
Antigens, Bacterial | 1 | 2008 | 18 | 0.080 |
Why?
|
Triglycerides | 1 | 2010 | 230 | 0.080 |
Why?
|
Flagellin | 1 | 2008 | 17 | 0.080 |
Why?
|
Bass | 1 | 2008 | 1 | 0.080 |
Why?
|
Vitellogenins | 1 | 2008 | 1 | 0.080 |
Why?
|
Fishes | 1 | 2008 | 8 | 0.080 |
Why?
|
Gene Expression | 1 | 2010 | 335 | 0.080 |
Why?
|
Breast Neoplasms | 2 | 2013 | 761 | 0.080 |
Why?
|
Oligonucleotides, Antisense | 1 | 2008 | 30 | 0.080 |
Why?
|
Gene Silencing | 1 | 2008 | 48 | 0.080 |
Why?
|
Mutation | 2 | 2012 | 488 | 0.080 |
Why?
|
Base Sequence | 4 | 2010 | 251 | 0.080 |
Why?
|
Fatty Acids | 1 | 2009 | 98 | 0.080 |
Why?
|
Deoxyguanosine | 1 | 2008 | 4 | 0.080 |
Why?
|
Rats | 2 | 2010 | 1596 | 0.080 |
Why?
|
Tryptases | 1 | 2008 | 1 | 0.080 |
Why?
|
Kininogen, High-Molecular-Weight | 1 | 2008 | 6 | 0.080 |
Why?
|
Pancreatic Elastase | 1 | 2008 | 4 | 0.080 |
Why?
|
Ferritins | 1 | 2008 | 46 | 0.080 |
Why?
|
Hydroxymethylglutaryl-CoA Synthase | 1 | 2007 | 1 | 0.080 |
Why?
|
Aldehydes | 1 | 2007 | 5 | 0.080 |
Why?
|
Body Composition | 1 | 2010 | 396 | 0.080 |
Why?
|
Mitochondria, Liver | 1 | 2007 | 7 | 0.080 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 607 | 0.070 |
Why?
|
Laryngeal Diseases | 1 | 2007 | 10 | 0.070 |
Why?
|
Oxidoreductases | 1 | 2007 | 26 | 0.070 |
Why?
|
Gastrointestinal Agents | 1 | 2006 | 7 | 0.070 |
Why?
|
Weight Loss | 1 | 2010 | 480 | 0.070 |
Why?
|
Larynx | 1 | 2006 | 20 | 0.070 |
Why?
|
Heat-Shock Proteins | 1 | 2006 | 34 | 0.070 |
Why?
|
Gastric Juice | 1 | 2005 | 1 | 0.070 |
Why?
|
Laryngitis | 1 | 2005 | 2 | 0.070 |
Why?
|
Neoplasms | 1 | 2012 | 692 | 0.060 |
Why?
|
Esophagitis, Peptic | 1 | 2004 | 1 | 0.060 |
Why?
|
Carbonic Anhydrase III | 1 | 2004 | 1 | 0.060 |
Why?
|
Escherichia coli Proteins | 1 | 2004 | 34 | 0.060 |
Why?
|
Humans | 11 | 2013 | 32025 | 0.060 |
Why?
|
Mass Spectrometry | 3 | 2012 | 103 | 0.060 |
Why?
|
Photochemistry | 3 | 2008 | 7 | 0.060 |
Why?
|
United States | 1 | 2012 | 3938 | 0.060 |
Why?
|
Cell Line, Tumor | 3 | 2012 | 725 | 0.060 |
Why?
|
Protein Binding | 3 | 2008 | 201 | 0.050 |
Why?
|
Female | 7 | 2013 | 19954 | 0.050 |
Why?
|
Photochemical Processes | 2 | 2011 | 3 | 0.050 |
Why?
|
Blotting, Western | 3 | 2007 | 292 | 0.050 |
Why?
|
Transfection | 2 | 2012 | 191 | 0.040 |
Why?
|
Peptides | 2 | 2012 | 119 | 0.040 |
Why?
|
Enzyme Activation | 2 | 2010 | 135 | 0.040 |
Why?
|
DNA Primers | 2 | 2009 | 90 | 0.040 |
Why?
|
RNA | 2 | 2010 | 92 | 0.040 |
Why?
|
Kinetics | 2 | 2009 | 209 | 0.040 |
Why?
|
Molecular Structure | 2 | 2008 | 59 | 0.040 |
Why?
|
Isoenzymes | 2 | 2009 | 61 | 0.040 |
Why?
|
Protein Structure, Tertiary | 2 | 2007 | 99 | 0.040 |
Why?
|
Binding Sites | 2 | 2008 | 130 | 0.030 |
Why?
|
Hydrogen-Ion Concentration | 2 | 2007 | 66 | 0.030 |
Why?
|
HSP70 Heat-Shock Proteins | 2 | 2007 | 26 | 0.030 |
Why?
|
Laryngeal Mucosa | 2 | 2007 | 3 | 0.030 |
Why?
|
Isoleucine | 2 | 2006 | 7 | 0.030 |
Why?
|
Prospective Studies | 3 | 2007 | 2283 | 0.030 |
Why?
|
Gastric Acidity Determination | 2 | 2005 | 4 | 0.030 |
Why?
|
Prognosis | 2 | 2013 | 1505 | 0.030 |
Why?
|
Probability | 2 | 2005 | 158 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2005 | 594 | 0.030 |
Why?
|
Phosphoinositide Phospholipase C | 1 | 2012 | 3 | 0.030 |
Why?
|
Administration, Oral | 1 | 2013 | 182 | 0.030 |
Why?
|
Ligands | 1 | 2012 | 80 | 0.030 |
Why?
|
Patient Participation | 1 | 2013 | 82 | 0.030 |
Why?
|
Male | 5 | 2008 | 19196 | 0.020 |
Why?
|
Methods | 1 | 2011 | 11 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2013 | 526 | 0.020 |
Why?
|
Alkaline Phosphatase | 1 | 2011 | 38 | 0.020 |
Why?
|
Severity of Illness Index | 2 | 2005 | 900 | 0.020 |
Why?
|
Dietary Supplements | 1 | 2013 | 188 | 0.020 |
Why?
|
Cell Movement | 1 | 2012 | 170 | 0.020 |
Why?
|
Adult | 3 | 2013 | 9367 | 0.020 |
Why?
|
Aged | 3 | 2013 | 10340 | 0.020 |
Why?
|
Middle Aged | 3 | 2013 | 11868 | 0.020 |
Why?
|
Deoxyribonuclease BamHI | 1 | 2009 | 1 | 0.020 |
Why?
|
Deoxyribonuclease EcoRI | 1 | 2009 | 1 | 0.020 |
Why?
|
Deoxyribonucleases, Type II Site-Specific | 1 | 2009 | 4 | 0.020 |
Why?
|
DNA Cleavage | 1 | 2009 | 4 | 0.020 |
Why?
|
Spectrophotometry, Ultraviolet | 1 | 2009 | 18 | 0.020 |
Why?
|
Solubility | 1 | 2009 | 37 | 0.020 |
Why?
|
Templates, Genetic | 1 | 2009 | 2 | 0.020 |
Why?
|
Nucleosides | 1 | 2009 | 10 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2009 | 40 | 0.020 |
Why?
|
Point Mutation | 1 | 2009 | 27 | 0.020 |
Why?
|
Cell Line | 1 | 2010 | 435 | 0.020 |
Why?
|
Luciferases, Renilla | 1 | 2008 | 2 | 0.020 |
Why?
|
Phosphorothioate Oligonucleotides | 1 | 2008 | 2 | 0.020 |
Why?
|
Cloning, Molecular | 1 | 2009 | 75 | 0.020 |
Why?
|
Yersinia pestis | 1 | 2008 | 1 | 0.020 |
Why?
|
Toll-Like Receptor 5 | 1 | 2008 | 2 | 0.020 |
Why?
|
Drug Stability | 1 | 2008 | 8 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2008 | 43 | 0.020 |
Why?
|
Genes, Reporter | 1 | 2008 | 40 | 0.020 |
Why?
|
Drug Storage | 1 | 2008 | 4 | 0.020 |
Why?
|
Virulence Factors | 1 | 2008 | 11 | 0.020 |
Why?
|
Immunization, Secondary | 1 | 2008 | 11 | 0.020 |
Why?
|
RNA 3' Polyadenylation Signals | 1 | 2008 | 1 | 0.020 |
Why?
|
Sequence Homology | 1 | 2008 | 3 | 0.020 |
Why?
|
von Willebrand Factor | 1 | 2008 | 16 | 0.020 |
Why?
|
Antibodies, Bacterial | 1 | 2008 | 32 | 0.020 |
Why?
|
Temperature | 1 | 2008 | 55 | 0.020 |
Why?
|
Sequence Alignment | 1 | 2008 | 60 | 0.020 |
Why?
|
Phylogeny | 1 | 2008 | 55 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2008 | 168 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2008 | 103 | 0.020 |
Why?
|
Biocatalysis | 1 | 2008 | 20 | 0.020 |
Why?
|
Succinimides | 1 | 2008 | 2 | 0.020 |
Why?
|
Macrophages, Alveolar | 1 | 2008 | 12 | 0.020 |
Why?
|
Organophosphorus Compounds | 1 | 2008 | 33 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2008 | 33 | 0.020 |
Why?
|
Electrophoresis, Gel, Two-Dimensional | 1 | 2007 | 11 | 0.020 |
Why?
|
Zinc | 1 | 2008 | 32 | 0.020 |
Why?
|
Gastric Acid | 1 | 2007 | 1 | 0.020 |
Why?
|
Methionine Sulfoxide Reductases | 1 | 2007 | 3 | 0.020 |
Why?
|
Methionine | 1 | 2007 | 8 | 0.020 |
Why?
|
Esophagoscopy | 1 | 2007 | 19 | 0.020 |
Why?
|
Survival Analysis | 1 | 2008 | 488 | 0.020 |
Why?
|
Follow-Up Studies | 1 | 2013 | 2280 | 0.020 |
Why?
|
Macaca fascicularis | 1 | 2008 | 397 | 0.020 |
Why?
|
Sequence Analysis, DNA | 1 | 2007 | 137 | 0.020 |
Why?
|
Phenylalanine | 1 | 2006 | 5 | 0.020 |
Why?
|
Gene Library | 1 | 2006 | 8 | 0.020 |
Why?
|
Asparagine | 1 | 2006 | 6 | 0.020 |
Why?
|
Quality of Life | 1 | 2013 | 933 | 0.020 |
Why?
|
Fluorescence Resonance Energy Transfer | 1 | 2006 | 7 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2008 | 268 | 0.020 |
Why?
|
Peptide Library | 1 | 2006 | 6 | 0.020 |
Why?
|
Models, Chemical | 1 | 2006 | 34 | 0.020 |
Why?
|
Computational Biology | 1 | 2007 | 91 | 0.020 |
Why?
|
Microscopy, Confocal | 1 | 2006 | 65 | 0.020 |
Why?
|
Acid-Base Equilibrium | 1 | 2005 | 10 | 0.020 |
Why?
|
Radioimmunoassay | 1 | 2005 | 25 | 0.020 |
Why?
|
Swine | 1 | 2006 | 215 | 0.020 |
Why?
|
Rats, Sprague-Dawley | 1 | 2007 | 745 | 0.020 |
Why?
|
Bacterial Outer Membrane Proteins | 1 | 2004 | 7 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2005 | 155 | 0.020 |
Why?
|
Ethanol | 1 | 2007 | 186 | 0.020 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2004 | 36 | 0.020 |
Why?
|
Protein Precursors | 1 | 2004 | 22 | 0.020 |
Why?
|
Sampling Studies | 1 | 2004 | 45 | 0.020 |
Why?
|
Monitoring, Physiologic | 1 | 2005 | 73 | 0.020 |
Why?
|
Protein Conformation | 1 | 2004 | 84 | 0.020 |
Why?
|
Aged, 80 and over | 1 | 2013 | 4000 | 0.020 |
Why?
|
Tissue Culture Techniques | 1 | 2004 | 40 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2007 | 247 | 0.020 |
Why?
|
Amino Acids | 1 | 2004 | 47 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2004 | 95 | 0.010 |
Why?
|
Analysis of Variance | 1 | 2005 | 464 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2004 | 298 | 0.010 |
Why?
|
Inflammation | 1 | 2008 | 540 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2006 | 833 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2004 | 532 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2004 | 897 | 0.010 |
Why?
|
Cohort Studies | 1 | 2005 | 1831 | 0.010 |
Why?
|
Risk Assessment | 1 | 2004 | 1435 | 0.010 |
Why?
|
Adolescent | 1 | 2006 | 3526 | 0.010 |
Why?
|